目的 探讨2023—2025年辽宁省肿瘤医院抗肿瘤靶向药物注射剂的使用情况，为该类药物的安全合理经济用药及规范化管理提供参考依据。方法 收集2023年1月1日—2025年12月31日辽宁省肿瘤医院抗肿瘤靶向药物注射剂的使用数据，逐年分析销售金额、用药频度（DDDs）、限定日费用（DDC）以及排序比（B/A）。结果 2023—2025年辽宁省肿瘤医院抗肿瘤靶向药物注射剂的销售总额逐年上升。贝伐珠单抗、曲妥珠单抗和帕妥珠单抗的销售金额在近3年稳居在前3位。地舒单抗的DDDs在2024年和2025年均位于第1位。替雷利珠单抗的销售金额和DDDs值在近3年逐年上涨。2023—2025年，辽宁省肿瘤医院抗肿瘤靶向药物注射剂的DDC值逐年下降，其中卡度尼利单抗的DDC值大幅度下降。地舒单抗的DDC值比较低，B/A远大于1。结论 辽宁省肿瘤医院在2023—2025年抗肿瘤靶向药物注射剂的使用较为合理，符合国家政策要求及肿瘤治疗的发展趋势。

Objective To analyze and discuss the use of anti-tumor targeted drug injections in Liaoning Cancer Hospital from 2023 to 2025, and provide a reference for the rational application and standardized management. Methods To collect the usage data of anti-tumor targeted drug injections in Liaoning Cancer Hospital from January 1, 2023 to December 31, 2025, and analyze the sales amount, DDDs, DDC, and B/A year by year. Results The total sales of anti-tumor targeted drug injections in Liaoning Cancer Hospital from 2023 to 2025 have been increasing year by year. The sales amounts of bevacizumab, trastuzumab, and pertuzumab consistently ranked among the top three in the past three years. DDDs of denosumab remained at the top position in both 2024 and 2025. The sales amount and DDD value of tislelizumab have been increasing year by year over the past three years. From 2023 to 2025, the DDC value of anti-tumor targeted drug injections in Liaoning Cancer Hospital decreased year by year, among which the DDC value of cadonilimab dropped significantly. The DDC value of denosumab is relatively low, and B/A is much greater than 1. Conclusion The use of anti-tumor targeted drug injections in Liaoning Cancer Hospital was relatively reasonable during the period of 2023 to 2025, which was in line with national policy requirements and the development trend of tumor treatment.

R979.1